Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03229200
Title Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Recruitment Enrolling by invitation
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Pharmacyclics Switzerland GmbH
Indications

lymphoma

leukemia

Advanced Solid Tumor

Therapies

Ibrutinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN


No variant requirements are available.